Omvoh 300 mg concentrate for solution for infusion

DRUG2 trials

Sponsors

Eli Lilly & Co., Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Conditions

Crohn's DiseaseModerately to Severely Active Ulcerative Colitis

Phase 3

I6T-MC-AMBA - A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moderately to Severely Active Ulcerative Colitis

Active, not recruitingCTIS2022-502183-20-00

Eli Lilly & Co.Moderately to Severely Active Ulcerative Colitis

Start: 2024-02-26Target: 30Updated: 2025-11-27

Phase 4

Efficacy of MIrikizumab to achieve traNsmural healing in patiENTs with Crohn’s Disease : EMINENT CD

Not yet recruitingCTIS2025-521889-95-00

Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube DigestifCrohn's Disease

Target: 110Updated: 2026-02-05